Joseph A. Pidala

Hematology | Oncology
12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 265 publications

Umbilical Cord Blood Donor Outcomes in BMTCTN1702.

Umbilical Cord Blood Donor Outcomes in BMTCTN1702.

Journal: Blood advances
Published: August 03, 2026

Plasma proteins associated with chronic graft-versus-host disease organ involvement.

Plasma proteins associated with chronic graft-versus-host disease organ involvement.

Journal: JCI insight
Published: July 28, 2026

Acalabrutinib for Treatment of Steroid-Refractory Chronic Graft Versus Host Disease.

Acalabrutinib for Treatment of Steroid-Refractory Chronic Graft Versus Host Disease.

Journal: Transplantation and cellular therapy
Published: July 08, 2026

Correction: Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Correction: Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Journal: Journal of cancer education : the official journal of the American Association for Cancer Education
Published: June 19, 2026

Chronic GVHD Consortium CATCH Study: Incidence, initial presentation and risk factors for chronic GVHD development.

Chronic GVHD Consortium CATCH Study: Incidence, initial presentation and risk factors for chronic GVHD development.

Journal: Blood advances
Published: June 08, 2026

Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" Trial.

Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" Trial.

Journal: American journal of hematology
Published: May 18, 2026

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

Journal: Blood advances
Published: April 08, 2026

Donor type outcomes in setting of PTCy: more apparent than real?

Donor type outcomes in setting of PTCy: more apparent than real?

Journal: Blood advances
Published: March 24, 2026

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Journal: Blood advances
Published: March 09, 2026

Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial.

Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial.

Journal: Blood advances
Published: March 09, 2026

Discordance in Treatment Response Assessment Between Clinicians and Patients With Skin Chronic Graft-vs-Host Disease.

Discordance in Treatment Response Assessment Between Clinicians and Patients With Skin Chronic Graft-vs-Host Disease.

Journal: JAMA dermatology
Published: January 21, 2026

Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT).

Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT).

Journal: Bone marrow transplantation
Published: January 13, 2026
Showing 1-12 of 265

Last Updated: 09/26/2026